國立虎尾科技大學 |

Biological Mechanisms of Minimal Residual Disease and Systemic Cancer

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Biological Mechanisms of Minimal Residual Disease and Systemic Cancer/ edited by Julio A. Aguirre-Ghiso.
其他作者:	Aguirre-Ghiso, Julio A.
面頁冊數:	IX, 162 p. 13 illus., 10 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-319-97746-1
ISBN:	9783319977461

Biological Mechanisms of Minimal Residual Disease and Systemic Cancer
Biological Mechanisms of Minimal Residual Disease and Systemic Cancer[electronic resource] /edited by Julio A. Aguirre-Ghiso. - 1st ed. 2018. - IX, 162 p. 13 illus., 10 illus. in color.online resource. - Advances in Experimental Medicine and Biology,11000065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Preface -- Foreword. Understanding and targeting minimal residual disease: a path to change cancer patient outcomes -- Epigenetics and Pluripotency Aspects of Disseminated Cancer Cells during Minimal Residual Disease -- Anti-angiogenic therapy-mediated endothelial damage: A driver of breast cancer recurrence?- Minimal Residual Disease in Prostate Cancer -- Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer -- Detection of Minimal Residual Disease and its Clinical Applications in Melanoma and Breast Cancer Patients Selena -- Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.-Minimal Residual Disease in Acute Myeloid leukemia -- Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia -- Minimal Residual Disease in Multiple Myeloma: Impact on response assessment, prognosis and tumor heterogeneity -- Index. .

This book focuses on the biological mechanisms of minimal residual disease (MRD) and recurrence. It integrates this biology in solid cancers and in hematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into technologies for molecular phenotyping of MRD and monitoring of CTCs, DTCs and cell free RNA and DNA are also addressed extensively. Five chapters explore the above concepts in solid cancers such as prostate, breast, melanoma, head and neck and esophageal. Two chapters also explore the basic mechanisms of vascular biology targeting and epigenetic mechanisms regulating pluripotency programs during dormancy. Similar biology is explored in hematological malignancies such as T-ALL, CML, AML and multiple myeloma in additional four chapters. This book is edited and prefaced by Dr. Julio Aguirre-Ghiso, an expert in dormancy and recurrence. The chapters are written by world-recognized experts Drs. Ravi Bahtia, Samir Parekh, Russel Taichman, Monica Guzman, David Hoon, Denis Schewe, Irmela Jeremias, Cyrus Ghajar, Maria Soledad Sosa and Nicholas Stoecklein. The topic of this book is of particular interest to both basic cancer cell biologists and physician scientists that are working to provide a more integrated view of the biology of MRD and to those interested in working on or learning about this paradigm. The integrated and cross-disciplinary focus of the book from biology to medicine seeks to help bridge gaps to improve cancer care and prevent recurrences.

ISBN: 9783319977461

Standard No.: 10.1007/978-3-319-97746-1doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Biological Mechanisms of Minimal Residual Disease and Systemic Cancer
LDR:04090nam a22003975i 4500 001 989948
003 DE-He213
005 20200706055227.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319977461 $9 978-3-319-97746-1
024 7 $a 10.1007/978-3-319-97746-1 $2 doi
035 $a 978-3-319-97746-1
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Biological Mechanisms of Minimal Residual Disease and Systemic Cancer $h [electronic resource] / $c edited by Julio A. Aguirre-Ghiso.
250 $a 1st ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a IX, 162 p. 13 illus., 10 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 1100
505 0 $a Preface -- Foreword. Understanding and targeting minimal residual disease: a path to change cancer patient outcomes -- Epigenetics and Pluripotency Aspects of Disseminated Cancer Cells during Minimal Residual Disease -- Anti-angiogenic therapy-mediated endothelial damage: A driver of breast cancer recurrence?- Minimal Residual Disease in Prostate Cancer -- Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer -- Detection of Minimal Residual Disease and its Clinical Applications in Melanoma and Breast Cancer Patients Selena -- Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.-Minimal Residual Disease in Acute Myeloid leukemia -- Characteristics and therapeutic targeting of minimal residual disease in childhood acute lymphoblastic leukemia -- Minimal Residual Disease in Multiple Myeloma: Impact on response assessment, prognosis and tumor heterogeneity -- Index. .
520 $a This book focuses on the biological mechanisms of minimal residual disease (MRD) and recurrence. It integrates this biology in solid cancers and in hematological malignancies. It reports also on technological advancements for monitoring MRD, derived from mechanistic insights. Chapters in solid and hematological malignancies address stem cell biology, genetics, epigenetics and micro-environmental regulation of dormant MRD. Novel insight into technologies for molecular phenotyping of MRD and monitoring of CTCs, DTCs and cell free RNA and DNA are also addressed extensively. Five chapters explore the above concepts in solid cancers such as prostate, breast, melanoma, head and neck and esophageal. Two chapters also explore the basic mechanisms of vascular biology targeting and epigenetic mechanisms regulating pluripotency programs during dormancy. Similar biology is explored in hematological malignancies such as T-ALL, CML, AML and multiple myeloma in additional four chapters. This book is edited and prefaced by Dr. Julio Aguirre-Ghiso, an expert in dormancy and recurrence. The chapters are written by world-recognized experts Drs. Ravi Bahtia, Samir Parekh, Russel Taichman, Monica Guzman, David Hoon, Denis Schewe, Irmela Jeremias, Cyrus Ghajar, Maria Soledad Sosa and Nicholas Stoecklein. The topic of this book is of particular interest to both basic cancer cell biologists and physician scientists that are working to provide a more integrated view of the biology of MRD and to those interested in working on or learning about this paradigm. The integrated and cross-disciplinary focus of the book from biology to medicine seeks to help bridge gaps to improve cancer care and prevent recurrences.
650 0 $a Cancer research. $3 1253664
650 0 $a Human genetics. $3 596505
650 0 $a Molecular biology. $3 583443
650 0 $a Cell biology. $3 1253486
650 0 $a Drug resistance. $3 872072
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Human Genetics. $3 593893
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Cell Biology. $3 593889
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Aguirre-Ghiso, Julio A. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1210948
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319977454
776 0 8 $i Printed edition: $z 9783319977478
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-319-97746-1
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)